moclobemide has been researched along with Burning Mouth Syndrome in 1 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Burning Mouth Syndrome: A group of painful oral symptoms associated with a burning or similar sensation. There is usually a significant organic component with a degree of functional overlay; it is not limited to the psychophysiologic group of disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pekiner, FN | 1 |
| Gumru, B | 1 |
| Ozbayrak, S | 1 |
1 trial available for moclobemide and Burning Mouth Syndrome
| Article | Year |
|---|---|
Efficacy of moclobemide in burning mouth syndrome: a nonrandomized, open-label study.
Topics: Analysis of Variance; Antidepressive Agents; Anxiety; Burning Mouth Syndrome; Case-Control Studies; | 2008 |